Ubrogepant vs. Triptans: Superior Relief for Migraine Sufferers

Research Summary

A recent study published in the journal Pain Management explored the real-world effectiveness of ubrogepant compared to triptans for acute migraine treatment. Conducted over four weeks, the study involved 211 participants who had switched from one oral triptan to either another triptan or ubrogepant. Results showed that those who switched to ubrogepant experienced significantly higher satisfaction in treating migraine pain and alleviating symptoms, with 69.4% reporting satisfaction compared to 42.0% in the triptan group. Additionally, 75.7% of the ubrogepant group preferred it over their previous triptan, reporting better relief within two hours. Overall, ubrogepant demonstrated superior outcomes.

Study Details

📄 Title: Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

👥 Research Team: Lipton RB et al.

📚 Published In: Pain Manag

📅 Publication Date: 2025 Nov 19

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.